Amgen/TKT EPO
Executive Summary
Transkaryotic Therapies gene-activated erythropoietin product does not literally fall within the scope of Amgen's process Patent No. 5,618,698 or No. 5,621,080, which claims certain EPO glycoproteins, Boston federal court Judge William Young ruled June 9. However, if TKT's EPO is equivalent to the product claimed by the '080 patent, it may be found to infringe the patent, Amgen said. Young also denied TKT and partner Aventis' motion for noninfringement of Patent No. 5,547,933. The trial will resume June 12 (1"The Pink Sheet" May 22, p. 28)